Nonapeptide analogues containing (R)-3-hydroxybutanoate and beta-homoalanine oligomers: synthesis and binding affinity to a class I major histocompatibility complex protein.
Crystal structures of antigenic peptides bound to class I MHC proteins suggest that chemical modifications of the central part of the bound peptide should not alter binding affinity to the MHC restriction protein but could perturb the T-cell response to the parent epitope. In our effort in designing nonpeptidic high-affinity ligands for class I MHC proteins, oligomers of (R)-3-hydroxybutanoate and(or) beta-homoalanine have been substituted for the central part of a HLA-B27-restricted T-cell epitope of viral origin. The affinity of six modified peptides to the B2705 allele was determined by an in vitro stabilization assay. Four out of the six designed analogues presented an affinity similar to that of the parent peptide. Two compounds, sharing the same stereochemistry (R,R,S,S) at the four stereogenic centers of the nonpeptidic spacer, bound to B2705 with a 5-6-fold decreased affinity. Although the chiral spacers do not strongly interact with the protein active site, there are configurations which are not accepted by the MHC binding groove, probably because of improper orientation of some lateral substituents in the bound state and different conformational behavior in the free state. However we demonstrate that beta-amino acids can be incorporated in the sequence of viral T-cell epitopes without impairing MHC binding. The presented structure-activity relationships open the door to the rational design of peptide-based vaccines and of nonnatural T-cell receptor antagonists aimed at blocking peptide-specific T-cell responses in MHC-associated autoimmune diseases.
Laboratory for Organic Chemistry, Swiss Federal Institute of Technology, Universitätstrasse 16, CH-8092 Zürich, Switzerland.
S
S
Poenaru
J R
JR
Lamas
G
G
Folkers
J A
JA
López de Castro
D
D
Seebach
D
D
Rognan
D020155:3-Hydroxybutyric Acid / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism; D000409:Alanine / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism; D000483:Alleles; D000818:Animals; D002460:Cell Line; D000939:Epitopes; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D015497:HIV-1; D015796:HLA-B27 Antigen / Q000378:metabolism*; D006885:Hydroxybutyrates; D008024:Ligands; D008958:Models, Molecular; D009842:Oligopeptides / Q000737:chemistry* / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry* / Q000378:metabolism; D011108:Polymers; D011485:Protein Binding; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D000939:Epitopes; D015699:HIV Envelope Protein gp120; D015796:HLA-B27 Antigen; D006885:Hydroxybutyrates; D008024:Ligands; D009842:Oligopeptides; D010446:Peptide Fragments; D011108:Polymers; D000409:Alanine; D020155:3-Hydroxybutyric Acid